Close Menu

This article has been updated to include information from a Thermo Fisher Scientific conference call.

NEW YORK – Thermo Fisher Scientific will acquire Qiagen for $11.5 billion, the companies announced early Tuesday morning.

Thermo Fisher will pay €39 ($43.35) per share of Qiagen's stock in cash, representing a premium of about 23 percent on the closing price of Qiagen's common stock on the Frankfurt Prime Standard on March 2, the last trading day prior to the announcement of the deal. The deal also includes the assumption of about $1.4 billion of net debt.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.